Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BellBrook Labs, which develops detection reagents and micro fluidic devices that accelerate the discovery of therapies for cancer and other debilitating diseases, has received a fourth US patent for its glycosyltransferase assay Transcreener HTS Assay.
Subscribe to our email newsletter
The new patent, US 7,847,066, describes the invention of a universal assay for UDP-glycosyltransferases based on direct detection of UDP in a high-throughput format.
BellBrook Labs claims with the Transcreener UDP Assay the detection of UDP produced in the enzyme reaction allows for a universal system to measure UDP-glycosyltransferase activity with any acceptor substrate.
The Transcreener HTS Assay offers advantages over other assay methods that require separation steps, as it allows homogenous and mix-and-read detection, the company said.
In combination with existing Transcreener assays for GDP and CMP, the new technology is expected to accelerate the discovery of improved drugs targeting glycosylation events in diseases, such as neurodegeneration, type II diabetes and cancer.